SuperworthNeonc Technologies NTHI
- Market cap
- $84.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Neonc Technologies' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| $43K | $20K | $0 | $20K | $40K−7% | $0 | $0 | $0 | n/a | n/a | |
| R&D | $614.5K | $394.5K | $956.7K | $1.1M | $998.2K+62% | $677.3K+72% | $715K−25% | $1.2M+16% | $1.3M+29% | $2.6M+291% |
| SG&A | $415.6K | $289.7K | $243.7K | $705.7K | $849.5K+104% | $984.3K+240% | $903K+271% | $2.1M+195% | $488.7K−43% | $895.6K−9% |
| −$1.6M | −$1.3M | −$2.2M | −$2.1M | −$31.9M+1956% | −$5.7M+346% | −$6.9M+216% | −$13.7M+548% | −$7.1M−78% | −$14.1M+147% | |
| Interest expense | $1.4M | $1.2M | $0 | −$2.4K | $308.9K−78% | $48.8K−96% | $869.8K | $1.3M | $982.6K+218% | $234.4K+381% |
| Net income | −$2.9M | −$4.5M | −$2.2M | −$2.3M | −$32.3M+1000% | −$5.7M+26% | −$8.6M+294% | −$15.5M+589% | −$8.8M−73% | −$14.2M+151% |
| −$0.18 | −$0.27 | −$0.12 | −$0.13 | −$1.78+889% | −$0.30+11% | −$0.45+275% | −$0.73+462% | −$0.38−79% | −$0.58+93% | |
| 16.6M | 16.6M | 17.9M | 17.3M | 18.1M+10% | 19M+14% | 19.2M+7% | 21.2M+23% | 23.3M+28% | 24.7M+30% |
EPS, diluted: Q4 FY24 and Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Neonc Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NTHINeonc Technologies | $84.8M | n/m | n/a | n/m | n/m | n/m | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $523.1M | 11.3× | 13.6× | 1.4× | +7% | 11.6% |
More on Neonc Technologies
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .